Evaluating the Long-term Safety of Apraglutide in Short Bowel Syndrome
Enrolling By Invitation
99 years or below
All
3 participants needed
1 Location
Brief description of study
The purpose of this extension trial is to find out how safe and how well the trial drug, apraglutide, is tolerated when you are treated for up to 104 weeks and to see if there are any changes in how much parenteral support (PS) you need.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Medical Research,Short Bowel Syndrome
-
Age: 99 years or below
-
Gender: All
Completed either the “STARS” trial (TA799-007) or the metabolic balance trial (TA799-013).
Updated on
04 Aug 2024.
Study ID: 850537
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
